Earnings call
Indoco Remedies Q1 FY26 earnings call: Indoco Remedies Limited expects to repay about Rs. 68 crores of loans in the remaining 9 months, as planned
By DalalOS Data Desk. Assembled by software from the company's transcript. Not reviewed by a person.
Transcript filed .
The company expects to repay about Rs. 68 crores of loans in the remaining 9 months, as planned. Standalone net revenues in Q1 FY '26 were Rs. 3,838 million, compared to Rs. 3,942 million in the same quarter last year and Rs. 3,411 million in the immediately preceding quarter, showing 12.5% growth on Q4 FY '25. Consolidated short-term and long-term debt together was Rs. 951 crore on 30th June, reduced by about Rs. 21 crore compared with March 25, after loan repayment as per the repayment schedule.
The numbers management gave
Results
- Standalone net revenues in Q1 FY '26 were Rs. 3,838 million, compared to Rs. 3,942 million in the same quarter last year and Rs. 3,411 million in the immediately preceding quarter, showing 12.5% growth on Q4 FY '25.
Show source
Let me first begin with the business highlights: Standalone net revenues of the Company for the 1st Quarter 2025-26 are at Rs. 3,838 million compared to Rs. 3,942 million for the same quarter last year and Rs. 3,411 million for the immediately preceding quarter, showing a 12.5% growth on Q4 FY '25.
- Consolidated net revenues in Q1 FY '26 were Rs. 4,291 million, compared to Rs. 4,243 million in the same quarter last year and Rs. 3,839 million in the immediately preceding quarter.
Show source
Consolidated net revenues of the Company for the 1st Quarter FY '25-‘26 are at Rs. 4,291 million compared to Rs. 4,243 million for the same quarter last year and Rs. 3,839 million for the immediately preceding quarter.
- Standalone EBITDA to net sales in Q1 FY '26 was 3.9%, compared to 13.1% in the same quarter last year and 1% in the immediately preceding quarter.
Show source
Standalone EBITDA to net sales for the quarter is 3.9% compared to 13.1% for the same quarter last year.
- Consolidated EBITDA to net sales in Q1 FY '26 was 4.1%, compared to 11.3% last year; it was negative in the preceding quarter.
Show source
Consolidated EBITDA to net sales for the quarter is 4.1% compared to 11.3% last year and for the preceding quarter , we were negative.
- Domestic formulation business revenues in Q1 FY '26 were Rs. 2,028 million, compared to Rs. 2,002 million in the same quarter last year.
Show source
Domestic formulation business: Revenues from domestic formulation business for the quarter are at Rs. 2,028 million compared to Rs. 2,002 million for the same quarter last year.
- Major therapeutic segments—Gastrointestinal, Anti-infective, Stomatology and Respiratory—performed well in Q1 FY '26 compared to last year.
Show source
Major therapeutic segments like Gastrointestinal, Anti-infective, Stomatology and Respiratory performed well during the quarter as compared to last year.
Show 11 more statements
Results
- International formulation business revenues in Q1 FY '26 were Rs. 1,393 million, compared to Rs. 1,571 million in the same quarter last year.
Show source
On the international business front: Page 3 of 12 Indoco Remedies Limited July 24, 2025 Revenues from international formulation business are at Rs. 1,393 million compared to Rs. 1,571 million for the same quarter last year.
- Revenues from reg markets in Q1 FY '26 were Rs. 950 million, against Rs. 1,273 million.
Show source
Revenues from reg markets for the quarter are at Rs. 950 million against Rs. 1,273 million.
- Revenues from US business in Q1 FY '26 were Rs. 283 million, against Rs. 487 million.
Show source
Revenues from US business are at Rs. 283 million against Rs. 487 million.
- Revenues from Europe in Q1 FY '26 were Rs. 635 million, against Rs. 754 million, and revenues from South Africa, Australia, New Zealand were Rs. 32 million, the same figure as last year.
Show source
For Europe, for the quarter, we are at Rs. 635 million against Rs. 754 million and for South Africa, Australia, New Zealand at Rs. 32 million compared to the same figure last year.
- Revenues from emerging markets in Q1 FY '26 were Rs. 443 million, against Rs. 298 million.
Show source
Revenues from emerging markets are at Rs. 443 million as against Rs. 298 million.
- API business revenues in Q1 FY '26 were Rs. 366 million, against Rs. 312 million.
Show source
And for the API business, we are at Rs. 366 million against Rs. 312 million.
- Revenues from AnaCipher CRO and Indoco Analytical Solutions in Q1 FY '26 were Rs. 50 million, against Rs. 57 million.
Show source
Revenues from AnaCipher CRO and Indoco Analytical Solutions are at Rs. 50 million against Rs. 57 million.
- Finance cost includes about Rs. 5.5-Rs. 6 crores of foreign-exchange loss on account of mark to market.
Show source
That includes close to about Rs. 5.5-Rs. 6 crores.
- Finance cost increased slightly because of its overall exposure to long-term and short-term borrowings.
Show source
But definitely it has increased slightly on account of overall exposure to the long-term and the short-term borrowings, what we have at this point of Page 5 of 12 Indoco Remedies Limited July 24, 2025 time.
Money and capital
- Consolidated short-term and long-term debt together was Rs. 951 crore on 30th June, reduced by about Rs. 21 crore compared with March 25, after loan repayment as per the repayment schedule.
Show source
So Mr. Nirmam, debt level at this point of time, that is on 30th June, is overall at consolidation level, short term and long term put together is Rs. 951 crore, which is reduced by about Rs. 21 crore as compared to March 25.
- The company had already repaid about Rs. 21 crores in 1st Quarter and will repay about Rs. 68 crores in the remaining 9 months as per its current plan.
Show source
In remaining 9 months, we will be repaying about Rs. 68 crores as per our current plan.
What it expects ahead
What management expects
- The company expects to repay about Rs. 68 crores of loans in the remaining 9 months, as planned.
Show source
The second part of the question, we expect another loan repayment in the coming period in 9 months, about Rs. 68 crores repayment, which is planned for the remaining 9 months.
What the company said on its earnings call, taken from its own transcript. Not advice.
Questions and answers
Question
Aditi Panandikar: Yes. So again, if you look at domestic IRL alone, yes, it is flat. But with Warren OTC in toto, the Company has shown a growth of on Y-o-Y basis about 5% and on Q-o-Q basis around 14%. But 1st Quarter for most companies is challenging because it comes after the March, which is typically a big billing month for most people who have to finish their target s. So the way to look at India business performance was would be to look at our performance possibly as shown in IQVIA, which is absolute third party. So, if you look at the IQVIA analysis of 1st Quarter performance, then for the industry, Q1, for the covered market, there has been a growth of 8% and for Indoco Remedies, the
Answer, sundeep bambolkar
Sundeep Bambolkar: Yes. So Mr. Nirmam, debt level at this point of time, that is on 30th June, is overall at consolidation level, short term and long term put together is Rs. 951 crore, which is reduced by about Rs. 21 crore as compared to March 25. So we have repaid a certain loan as per the repayment schedule. As regards to finance cost, it includes certain FX loss on account of mark to market. That includes close to about Rs. 5.5-Rs. 6 crores. If I remove that, then you can see the like-to-like comparison of finance cost. But definitely it has increased slightly on account of overall exposure to the long-term and the short-term borrowings, what we have at this point of Page 5 of 12 Indoco Remedies Limited July 24, 2025 time.
Answer, sundeep bambolkar
The second part of the question, we expect another loan repayment in the coming period in 9 months, about Rs. 68 crores repayment, which is planned for the remaining 9 months. Nirmam: Thank you. That is it from my side.
Question
Aditi Panandikar: I think, close to.
Answer, sundeep bambolkar
Sundeep Bambolkar: So for the quarter, it is Rs. 31.6 crores, overall.
Question
V. P. Rajesh: And how much do you think you will pay down this year?
Answer, pramod ghorpade
Pramod Ghorpade: So in remaining 9 months, so we have already paid about Rs. 21 crores in 1st Quarter. In remaining 9 months, we will be repaying about Rs. 68 crores as per our current plan.
Question
V. P. Rajesh: And my other question was on the other income line. So while it has come down quarter over quarter, but if you look at compared to last year, it is still significantly higher. So obviously, there is onetime cost regarding remediation and perhaps other related expenses, so what is sort of the sustainable business related other expenses? If you can just give a sens e of that, that will be helpful?
Answer, pramod ghorpade
Pramod Ghorpade: So remediation cost is nothing to do with other income as such.
Questions about this call
- When was the Indoco Remedies Q1 FY26 earnings call transcript filed?
- Indoco Remedies filed the transcript with the exchange on 28 Jul 2025. This page is built from that transcript.
- What does this page list?
- 18 statements from the transcript across 3 topics, 17 of them with a figure. Each statement is shown with the transcript sentence it came from.
- Are the analysts' questions included?
- Yes. 4 questions and management's answers are listed in the order they were asked, as the transcript prints them.
- Who wrote this page?
- DalalOS Data Desk. Assembled by software from the company's transcript. Not reviewed by a person. How it is made, and what it leaves out, is on the method page linked from the byline.